Gabapentin Capsule
Product Images NDC 70518-0053

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-0053). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin 400 mg oral capsules label from RemedyRepack Inc., packaging contains 30 capsules. The label includes NDC number 70518-0053-00, manufacturer Ascend Labs LLC, and storage instructions at 20-25°C with permitted excursions. It advises to keep medication out of children's reach and references package insert for directions.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A mathematical formula image showing the equation for calculating creatinine clearance (CLCr) involving variables including age in years, weight in kilograms, serum creatinine levels, and an adjustment factor for female patients.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph depicting mean pain scores over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents time in weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Gabapentin's mean pain scores decrease steadily compared to the relatively stable scores for placebo.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph depicting mean pain scores over 7 weeks, comparing placebo with gabapentin at doses of 1800 mg/day and 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period followed by a 4-week fixed dose period, while the y-axis shows mean pain scores ranging from 0 to 10. The graph illustrates trends for each group across the study duration.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) to Gabapentin (GBP) at different dosages in two separate studies. The y-axis represents the percentage of responders, with values ranging from 0% to 100%. Study 1 shows 12% for PBO and 29% for GBP 3600 mg. Study 2 shows 14% for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated at p < 0.01 and p < 0.001 levels.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot showing the relationship between daily dose (mg) on the x-axis and difference (%) on the y-axis. Data points are indicated for three studies labeled a, b, and c with varying doses approximately at 600 mg, 900 mg, 1200 mg, and 1800 mg. Study a is represented by black squares, Study b by gray squares, and Study c by white squares.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.